OR WAIT null SECS
August 08, 2023
The investigational drug was developed to activate a novel uptake pathway, allowing antineoplastic drugs to combat solid tumors more successfully.
August 07, 2023
BlueRock will be responsible for the global development and commercialization of therapeutic candidates emerging from this collaboration.
August 04, 2023
Under a manufacturing agreement, Northway Biotech will develop a manufacturing process for iTolerance’s fusion protein in development for regenerative therapy.
August 03, 2023
The nasal-spray drug can be used to reverse the effects of opioid overdose.
Laboratories are focusing on more automated processes while also trying to maintain an efficient, safe, and personalized experience with each analytical test.
August 01, 2023
Biogen’s acquisition of Reata will grant them access to Reata’s FDA-approved treatment for Friedreich’s ataxia.
AstraZeneca, via its subsidiary Alexion Pharmaceuticals, will purchase a portfolio of preclinical rare disease gene therapies from Pfizer in a deal worth up to $1 billion.
July 27, 2023
Teva Pharmaceuticals and Alvotech will expand their partnership for the development and commercialization of biosimilar candidates.
Roche will pay up to $2.8 billion for the rights to Alnylam’s RNA-based hypertension therapeutic.
Janssen has received a positive opinion from the EMA for two novel bispecific antibodies, TALVEY (talquetamab) and TECVAYLI (teclistamab), which the company is developing to treat blood cancer.